Omnes Capital's investments

Created in March 2014, Horama is developing new gene therapies for the treatment of hereditary retinopathies pigmentosa, which are orphan ophthalmological diseases. The company gathers the expertise of internationally renowned scientific experts in the field of ophthalmologic gene therapies. Its ambition is to help slow down visual loss and even improve the visual function by injecting a specific viral vector based on adeno-associated viruses (AAV). Horama’s scientific founding team (Nantes and Montpellier, France) is the first one in France to have completed an ophthalmology gene therapy study in 2011.

Launched in 2013 by two sisters, Hannah Oiknine and Sarah Azan, Babbler is a platform for exchanging content and news in real time between communications and media professionals (editors, journalists, bloggers etc.).
With the growing number of new channels of influence, the company offers a new approach to media relations drawing on the logic of social media: factoring in the ideas of community, engagement and data.
The tool acts as a real facilitator that can be used to optimise interaction between advertisers, communications/PR agencies and the media with a matching system on registering.
Journalists and influencers have access to targeted news based on their centres of interest, while advertisers benefit from live reports on monitoring of their publications and exchanges with journalists.
Around 4,000 journalists and influencers, for whom registration is free, and more than 300 advertisers use the platform.

Intersec designs innovative software enabling companies to leverage their Big Data. Our disruptive technology crunches and consolidates huge amounts of data coming from heterogeneous network equipment and IT, and turns them into actionable insights in real-time. Applications range from Customer Base Management, mass-scale Location-Based Services, Fraud Management and Business Analytics.